Recombinant Factor VIII for the Treatment of Previously Untreated ...

Recombinant factor VIII for the treatment of previously ... - PubMed

We conducted a multicenter trial in previously untreated children with hemophilia A. They received recombinant factor VIII for all treatment or for prophylaxis.

We conducted a multicenter trial in previously untreated children with hemophilia A. They received recombinant factor VIII for all treatment or for prophylaxis.

Recombinant Factor VIII for the Treatment of Previously Untreated ...

For this reason, the use of recombinant DNA-derived factor VIII (which is virus-free) to treat hemophilia A has generated considerable interest.

Recombinant factor VIII products and inhibitor development in ...

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014 Nov 27;124(23):3398-408. doi: ...

Recombinant factor VIII products and inhibitor development in ...

... untreated boys with severe hemophilia A ... Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated ...

Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients ...

In July 1990, the Recombinate Study Group initiated a prospective, open-labeled investigation of recombinant factor VIII (r-FVIII) to assess its safety and ...

Human recombinant DNA-derived antihemophilic factor in the ...

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Ko- genate ...

First study of extended half-life rFVIIIFc in previously untreated ...

, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A . J Thromb ...

Recombinant factor VIII for the treatment of previously untreated ...

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate ...

Clinical evaluation of B-domain deleted recombinant factor VIII in ...

The Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J ...

Status of Recombinant Factor VIII Concentrate Treatment ... - Frontiers

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood ...

Clinical Evaluation of a Recombinant Factor VIII Preparation ...

The safety and efficacy of a recombinant factor VIII (rFVIII) preparation (Kogenate) for the treatment of bleeding episodes was studied in previously untreated ...

RECOMBINATE™ [Antihemophilic Factor (Recombinant)] Official Site

The 69 patients with previous treatment of plasma-derived Factor VIII received RECOMBINATE treatment ... previously untreated patients with hemophilia A.

XYNTHA ® Lyophilized Powder References

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med. 1993;328:453–459. Bray GL, Gomperts ED, Courter ...

Human recombinant DNA-derived antihemophilic factor in the ...

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate ...

Recombinant factor VIII Fc for the treatment of haemophilia A

About one-third of previously untreated patients with severe haemophilia A develop inhibitors to FVIII products, which have a significant impact ...

NCT01712438 | Boston Children's Hospital

... Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients ... * No previous treatment with FVIII concentrates or other blood products containing ...

Recombinant factor VIII products and inhibitor development in ...

We conducted a combined analysis of individual patient data from three large studies in previously untreated patients (PUPs) with severe ...

Extended Half-Life Recombinant Factor VIII in Previously Untreated ...

As many of you may know, Eloctate was the first extended half-life product approved for the treatment and prevention of bleeds in patients of ...

[PDF] Recombinant factor VIII products and inhibitor development in ...

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. ... Intensity of factor VIII treatment ...